Back to top
more

CytoDyn (CYDY)

(Delayed Data from OTC)

$0.15 USD

0.15
287,889

0.00 (-1.01%)

Updated Apr 25, 2024 01:30 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (93 out of 251)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for CYDY

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Fiscal Year End for CytoDyn Inc falls in the month of May.

All items in Millions except Per Share data.

5/31/2023 5/31/2022 5/31/2021 5/31/2020 5/31/2019
Assets          
Cash & Equivalents 9 4 34 14 3
Receivables 0 0 0 0 0
Notes Receivable 0 0 0 0 0
Inventories 0 0 93 19 0
Other Current Assets 2 6 2 3 2
Total Current Assets 11 11 130 37 5
Net Property & Equipment 0 0 0 0 0
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 0 18 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 0 0 2 13 15
Deposits & Other Assets 0 0 0 0 0
Total Assets 11 29 132 51 21
Liabilities & Shareholders Equity 5/31/2023 5/31/2022 5/31/2021 5/31/2020 5/31/2019
Notes Payable 34 36 63 7 8
Accounts Payable 63 68 66 29 16
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 23 19 24 8 2
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 0 0 0 0 1
Total Current Liabilities 120 123 153 45 27
Mortgages 0 0 0 0 0
Deferred Taxes/Income 0 0 0 0 0
Convertible Debt 0 0 0 8 0
Long-Term Debt 1 0 0 0 0
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 0 0 0 0 2
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 121 124 153 53 30
Shareholders Equity 5/31/2023 5/31/2022 5/31/2021 5/31/2020 5/31/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 1 1 1 1 0
Capital Surplus 731 671 490 352 220
Retained Earnings -842 -766 -511 -355 -229
Other Equity 0 0 0 0 0
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity -110 -94 -21 -2 -9
Total Liabilities & Shareholder's Equity 11 29 132 51 21
Total Common Equity -110 -94 -21 -2 -9
Shares Outstanding 921.10 723.80 620.70 535.20 329.80
Book Value Per Share -0.12 -0.13 -0.03 0.00 -0.03

Fiscal Year End for CytoDyn Inc falls in the month of May.

All items in Millions except Per Share data.

2/29/2024 11/30/2023 8/31/2023 5/31/2023 2/28/2023
Assets          
Cash & Equivalents 8 7 9 9 11
Receivables 0 0 0 0 0
Notes Receivable 0 0 0 0 0
Inventories 0 0 0 0 0
Other Current Assets 2 2 3 2 3
Total Current Assets 10 9 12 11 14
Net Property & Equipment 0 0 0 0 0
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 0 0 0 0 0
Deposits & Other Assets 0 0 0 0 1
Total Assets 10 9 12 11 15
Liabilities & Shareholders Equity 2/29/2024 11/30/2023 8/31/2023 5/31/2023 2/28/2023
Notes Payable 30 33 33 34 36
Accounts Payable 62 62 63 63 63
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 31 28 26 23 23
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 6 0 7 0 0
Total Current Liabilities 129 123 129 120 121
Mortgages 0 0 0 0 0
Deferred Taxes/Income 0 0 0 0 0
Convertible Debt 0 0 0 0 0
Long-Term Debt 0 0 0 1 0
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 0 0 0 0
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 130 124 129 121 122
Shareholders Equity 2/29/2024 11/30/2023 8/31/2023 5/31/2023 2/28/2023
Preferred Stock 0 0 0 0 0
Common Stock (Par) 1 1 1 1 1
Capital Surplus 754 747 735 731 715
Retained Earnings -875 -863 -853 -842 -823
Other Equity 0 0 0 0 0
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity -119 -114 -117 -110 -107
Total Liabilities & Shareholder's Equity 10 9 12 11 15
Total Common Equity -119 -114 -117 -110 -107
Shares Outstanding 989.40 978.60 930.40 921.10 909.30
Book Value Per Share -0.12 -0.12 -0.13 -0.12 -0.12